mRNA drugs used for prevention and treatment of diseases
| Disease type | Name | Administration route |
|---|---|---|
| Infectious diseases | ||
| COVID-19 | NT162b2 | i.m. |
| mRNA-1273 | ||
| Rabies | RVG-SAM | i.m. |
| Cancer | ||
| A20-OVA lymphoma | OVA mRNA | i.v. |
| B16F10-OVA melanoma | OVA mRNA | i.v. |
| Hepa1-6 orthotopic HCC tumor | BisCCL2/5i mRNA | i.v. |
| Cardiovascular diseases | ||
| Familial hypercholesterolaemia and atherosclerotic cardiovascular diseases | mRNA encoding Cas9 | i.v. |
| Type 2 diabetes | VEGF-A mRNA | i.d. |
| Genetic disorder | ||
| Monogenic retinal degenerative disorders of retinal pigmented epithelium | EGFP mRNA | Subretinal injection |
| Methylmalonic acidemia | mRNA encoding human wild-type MCMUT | i.v. |
| Fabry disease | α-Gal A mRNA | i.v. |
CCL2: C-C motif chemokine ligand 2; EGFP: enhanced green fluorescence protein; HCC: hepatocellular carcinoma; MCMUT: methylmalonyl-coenzyme A (CoA)-mutase; RVG-SAM: self-amplifying RNA encoding the rabies virus glycoprotein; VEGF-A: vascular endothelial growth factor A; α-Gal A: alpha-galactosidase A